Please wait while the formulary information is being retrieved.
Drug overview for LEVOCARNITINE SF (levocarnitine):
Generic name: LEVOCARNITINE (lee-voh-KAR-nih-teen)
Drug class: Levocarnitine
Therapeutic class: Metabolic Modifiers
Levocarnitine is a naturally occurring amino acid derivative essential for mammalian energy metabolism.
No enhanced Uses information available for this drug.
Generic name: LEVOCARNITINE (lee-voh-KAR-nih-teen)
Drug class: Levocarnitine
Therapeutic class: Metabolic Modifiers
Levocarnitine is a naturally occurring amino acid derivative essential for mammalian energy metabolism.
No enhanced Uses information available for this drug.
DRUG IMAGES
LEVOCARNITINE SF 1 G/10 ML SOL
The following indications for LEVOCARNITINE SF (levocarnitine) have been approved by the FDA:
Indications:
Carnitine deficiency
Professional Synonyms:
BT factor deficiency
Vitamin BT deficiency
Indications:
Carnitine deficiency
Professional Synonyms:
BT factor deficiency
Vitamin BT deficiency
The following dosing information is available for LEVOCARNITINE SF (levocarnitine):
No enhanced Dosing information available for this drug.
Administer levocarnitine orally (as a solution or tablets) or by IV injection or infusion.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| LEVOCARNITINE SF 1 G/10 ML SOL | Maintenance | Adults take 10 milliliters (1 gram) by oral route 3 times per day with meals |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| LEVOCARNITINE SF 1 G/10 ML SOL | Maintenance | Adults take 10 milliliters (1 gram) by oral route 3 times per day with meals |
The following drug interaction information is available for LEVOCARNITINE SF (levocarnitine):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for LEVOCARNITINE SF (levocarnitine):
Drug contraindication overview.
*None.
*None.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Seizure disorder |
The following adverse reaction information is available for LEVOCARNITINE SF (levocarnitine):
Adverse reaction overview.
Common adverse effects reported with oral levocarnitine therapy include transient nausea and vomiting, abdominal cramps, diarrhea, and body odor. Common adverse effects reported with IV levocarnitine therapy include transient nausea and vomiting, body odor, and gastritis. Patients on chronic hemodialysis may experience injection site reactions, headache, pain, diarrhea, flu syndrome, pharyngitis, infection, hypertension, vomiting, abdominal pain, hypotension, dizziness, increased cough, chest pain, hypercalcemia, accidental injury, asthenia, nausea, fever, anemia, hypervolemia, paresthesia, rhinitis, or dyspnea.
Seizures were reported in patients, with or without preexisting seizure activity, receiving either oral or IV levocarnitine. Increased seizure frequency and/or severity also has been reported in patients with preexisting seizure activity.
Common adverse effects reported with oral levocarnitine therapy include transient nausea and vomiting, abdominal cramps, diarrhea, and body odor. Common adverse effects reported with IV levocarnitine therapy include transient nausea and vomiting, body odor, and gastritis. Patients on chronic hemodialysis may experience injection site reactions, headache, pain, diarrhea, flu syndrome, pharyngitis, infection, hypertension, vomiting, abdominal pain, hypotension, dizziness, increased cough, chest pain, hypercalcemia, accidental injury, asthenia, nausea, fever, anemia, hypervolemia, paresthesia, rhinitis, or dyspnea.
Seizures were reported in patients, with or without preexisting seizure activity, receiving either oral or IV levocarnitine. Increased seizure frequency and/or severity also has been reported in patients with preexisting seizure activity.
There are 5 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Anaphylaxis Bronchospastic pulmonary disease Laryngeal edema Muscle weakness Seizure disorder |
There are 9 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abdominal pain with cramps Diarrhea Nausea Vomiting |
Body odor Gastritis |
| Rare/Very Rare |
|---|
|
Facial edema Skin rash Urticaria |
The following precautions are available for LEVOCARNITINE SF (levocarnitine):
Dosage of levocarnitine in pediatric patients <=18 years of age was based on specific patient case record observations rather than on studies that specifically defined age by protocol.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
There are no adequate and well controlled studies with levocarnitine use in pregnant women. Animal reproduction studies have not shown any evidence of fetal harm. Use during pregnancy only if clearly needed.
Levocarnitine is distributed into milk in cows; it is not known whether the drug is distributed into human milk. Weigh risks and benefits of use in nursing mothers. The manufacturer recommends to consider discontinuance of nursing or the drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for LEVOCARNITINE SF (levocarnitine):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for LEVOCARNITINE SF (levocarnitine)'s list of indications:
| Carnitine deficiency | |
| E71.4 | Disorders of carnitine metabolism |
| E71.40 | Disorder of carnitine metabolism, unspecified |
| E71.41 | Primary carnitine deficiency |
| E71.42 | Carnitine deficiency due to inborn errors of metabolism |
| E71.43 | Iatrogenic carnitine deficiency |
| E71.44 | Other secondary carnitine deficiency |
| E71.448 | Other secondary carnitine deficiency |
Formulary Reference Tool